Sun Pharmaceutical Industries Limited Max Pain Analysis
What is Max Pain?
Max Pain theory states the underlying gravitates toward the strike where option writers face minimum collective loss at expiry. For SUNPHARMA, that strike is ₹1,920. Spot at ₹1,899 is 1.1% below max pain — possible upward gravitational pull into expiry.
Max Pain Level
The current max‑pain strike for Sun Pharmaceutical Industries Limited (SUNPHARMA) is ₹1,920. Max pain represents the strike at which option writers collectively suffer the smallest aggregate loss, so the price often drifts toward this level as expiration approaches.
Spot versus Max Pain Gap
The spot price sits at ₹1,899, about 1.09 % below the max‑pain strike. This modest gap suggests the market is pulling the underlying toward the pain point, with upside pressure potentially building as the expiry date closes in.
Shift Signal
The max‑pain level shows no shift versus yesterday, indicating a stable equilibrium for option writers. A static pain point signals that market participants have largely settled their positioning, reducing the likelihood of abrupt directional moves driven by writer rebalancing.
Expiry Context
Max pain emerges from the net open‑interest of all call and put series, where writers aim to minimize payout at a single strike. In the week of expiry, the underlying often gravitates toward this strike due to hedging activity, yet this is a statistical tendency rather than a deterministic outcome; other market forces can outweigh the pull. Consequently, while a convergence toward ₹1,920 is plausible, price can still deviate significantly on news or macro events.
Data Note
The spot price is ₹21 below the max‑pain level, with 25 days remaining until the September 29, 2026 expiration.
Data as of 2026-09-04